Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: iGenix, Illumina; Sigma-Aldrich; Becton Dickinson; UK's National Cancer Research Institute; SRU Biosystems

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Seattle-based iGenix has been named an Illumina certified service provider for the BeadXpress platform. iGenix said that it specializes in biomarker evaluation and helps clients develop new diagnostic assays for the BeadXpress platform.


Sigma-Aldrich said this week that its board of directors has declared a quarterly cash dividend of $.16 per share to be payable on Dec. 15 to shareholders of record on Dec. 1.


Becton Dickinson sold $1 billion worth of senior notes this past week. The firm sold $700 million of 3.25 percent notes due Nov. 12, 2020, and $300 million of 5 percent notes due Nov. 12, 2040.


The UK's National Cancer Research Institute has launched the UK Prostate Cancer Sample Collection Database. NCRI said that in addition to 10,000 biological samples taken from men in the UK with and without prostate cancer, the biobank will also hold other materials for research, including DNA, RNA, blood, and urine. The biobank will hold both clinical and molecular data.


SRU Biosystems is offering its newest label-free BIND Scanner to an academic or non-profit lab that wins its annual Label-free Technology Award. The Woburn, Mass.-based firm said the recipient of the award will be chosen based on "scientific merit, novelty of research, and the promise of advancing science and medicine using label-free technology.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more